CV Sciences Inc logo

CVSI - CV Sciences Inc News Story

$0.16 0.0  0.0%

Last Trade - 02/12/21

Sector
Healthcare
Size
Micro Cap
Market Cap £13.5m
Enterprise Value £13.9m
Revenue £15.6m
Position in Universe 6623rd / 7292

CV Sciences, Inc. to Announce First Quarter 2021 Results on May 13, 2021

Thu 6th May, 2021 12:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210506:nGNX26cWGy&default-theme=true


SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc.
(https://www.globenewswire.com/Tracker?data=7Ygb4S7QGRpjszyS9tG4LY38wqdonA6D8_nSspx16h0EcZiV4SyJ_husgcL4JsOGCz1IXtuPcnR7vI_53HA7Ig==)
(OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or
“we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)
products, today announced that it will release financial results for the first
quarter ended March 31, 2021, after the stock market closes on Thursday, May
13, 2021. The Company will hold a conference call with the investment
community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.

The webcast of the conference call will be available on the Investor Relations
section of the Company's website at https://ir.cvsciences.com/news-events and
at http://public.viavid.com/index.php?id=144697. The webcast will be archived
for approximately 30 days. Investors interested in participating in the live
call can also dial (877) 407-0784 from the U.S. or international callers can
dial (201) 689-8560. Please dial the conference telephone number 15 minutes
prior to the start time due to increased demand for conference calls.

A telephone replay will be available approximately two hours after the call
concludes and will be available through Thursday, May 20, 2021, by dialing
(844) 512-2921 from the U.S. or (412) 317-6671 from international locations,
and entering confirmation code 13719303.

About CV Sciences, Inc.

CV, or Curriculum Vitae, is Latin for "course of life", and science is the
pursuit of truth. CV Sciences: our name is our mission -improving quality of
life through nature and science.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a
consumer product division focused on manufacturing, marketing and selling
plant-based dietary supplements and CBD products to a range of market sectors;
and a drug development division focused on developing and commercializing
CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at
more than 7,300 retail locations throughout the U.S. and it is the top-selling
brand of hemp-derived CBD in the natural products market, according to SPINS,
the leading provider of syndicated data and insights for the natural, organic
and specialty products industry. CV Sciences follows all guidelines for Good
Manufacturing Practices (GMP) and the Company’s products are processed,
produced, and tested throughout the manufacturing process to confirm strict
compliance with company standards and specifications. With a commitment to
science, PlusCBD™ product benefits in healthy people are supported by human
clinical research data, in addition to three published clinical case studies
available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to
invest in the scientific evidence necessary to receive self-affirmed Generally
Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and
facilities in San Diego, California. Additional information is available from
OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results that are
forward looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risk and uncertainties.

CONTACT INFORMATION:

Investor Contact:
ICR
Reed Anderson
646-277-1260
CVSciences@icrinc.com

Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/cda334c6-52de-4df0-b0a2-55a02b8a5d52)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.